Dr. Reddy's Laboratories (RDY) Competitors

Dr. Reddy's Laboratories (NYSE:RDY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Is RDY or TAK more profitable?

Dr. Reddy's Laboratories has a net margin of 17.38% compared to Takeda Pharmaceutical's net margin of 2.36%. Dr. Reddy's Laboratories' return on equity of 17.98% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	17.38%	17.98%	12.24%
Takeda Pharmaceutical	2.36%	10.64%	5.14%

Do institutionals & insiders hold more shares of RDY or TAK?

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is RDY or TAK a better dividend stock?

Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.5%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.5%. Dr. Reddy's Laboratories pays out 12.1% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Which has more volatility and risk, RDY or TAK?

Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

Do analysts prefer RDY or TAK?

Dr. Reddy's Laboratories presently has a consensus target price of $16.95, indicating a potential upside of 12.40%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation & earnings, RDY or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.81B	3.30	$663M	$0.66	22.85
Takeda Pharmaceutical	$30.09B	1.64	$712.33M	$0.22	70.68

Does the media favor RDY or TAK?

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 2 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dr. Reddy's Laboratories beats Takeda Pharmaceutical on 11 of the 17 factors compared between the two stocks.